<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250626066260N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-11-21</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Dexmedetomidine on Hemodynamic Stability and Opioid Requirement in Pulmonary Hydatid Cyst Surgery</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Dexmedetomidine on Hemodynamic Stability and Opioid Requirement in Patients Undergoing Pulmonary Hydatid Cyst Surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/87428</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study entitled “The Effect of Dexmedetomidine on Hemodynamic Stability and Opioid Requirement in Patients Undergoing Pulmonary Hydatid Cyst Surgery,” block randomization was used. A total of 10 random blocks with variable block sizes of 4 and 6 and different random sequences were generated using the website https://www.sealedenvelope.com/simple-randomiser/v1/lists
. The contents of each block were placed in opaque, sealed, and sequentially numbered envelopes, and all blocks were randomly arranged. As each eligible patient was enrolled, the envelope corresponding to the current block was opened sequentially, and the patient was assigned to one of the two study arms (Dexmedetomidine group or Control group) according to the sequence inside. After completion of the first block, the next block was randomly selected, and this process continued until the last block was completed and the final patient was allocated. Consequently, patients were equally distributed between the two study arms, ensuring proper balance. The unit of randomization in this study was individual, and no stratified randomization was applied. For allocation concealment, the envelopes were prepared opaque, sealed, and sequentially numbered to prevent the investigator from knowing the intervention type prior to patient enrollment. The study was designed as a double-blind trial, in which both patients and the data analyst were blinded to group allocation, while the anesthesiologist administering the drug was aware of the allocation for safety monitoring and management of potential adverse effects, Blinding description: Participant: After receiving full information about the study protocol and providing written informed consent, participants remain unaware of their group allocation. Both dexmedetomidine and placebo solutions are prepared in identical syringes with the same volume and appearance by an independent staff member, ensuring that patients cannot distinguish their assigned intervention.

Investigator: The principal investigator does not participate in drug preparation or allocation procedures and remains blinded to group assignments throughout the data collection phase. Allocation codes are kept in sealed envelopes and will only be opened after completion of data analysis.

Outcome Assessor: The assessor responsible for recording hemodynamic variables, opioid consumption, postoperative pain scores, and clinical outcomes is fully blinded to the intervention type. The assessor works solely based on patient identification codes and has no access to information about drug assignment or administration.</study_design>
      <phase>3</phase>
      <hc_freetext>Pulmonary Hydatid Cyst.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Includes patients who, after induction of anesthesia, receive dexmedetomidine initially at a dose of 1 µg/kg over 10 minutes, followed by 0.5 µg/kg/h via intravenous infusion until the end of surgery. Intervention 2: Control group: Includes patients who, under the same anesthetic conditions, receive an equivalent volume of normal saline instead of dexmedetomidine at the same infusion rate (placebo). Other anesthetic management and therapeutic interventions are the same as in the intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Vahid Nourbakhsh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahmadabad Street, Qaem Hospital</address>
        <city>mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9176699199</zip>
        <telephone>+98 915 834 0408</telephone>
        <email>vhn041@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Alireza Sharifian Attar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahmadabad Street, Qaem Hospital</address>
        <city>mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9176699199</zip>
        <telephone>009153150596</telephone>
        <email>sharifiana@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18 and 65 years
Candidate for unilateral pulmonary hydatid cyst surgery (via thoracotomy or VATS)
Physical status ASA class I or II
Written informed consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B67.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Echinococcus granulosus infection, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Includes patients who, after induction of anesthesia, receive dexmedetomidine initially at a dose of 1 µg/kg over 10 minutes, followed by 0.5 µg/kg/h via intravenous infusion until the end of surgery.</i_keyword>
      <i_keyword>Control group: Includes patients who, under the same anesthetic conditions, receive an equivalent volume of normal saline instead of dexmedetomidine at the same infusion rate (placebo). Other anesthetic management and therapeutic interventions are the same as in the intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Systolic and diastolic blood pressure. Timepoint: Before induction of anesthesia; after surgical incision; every fifteen minutes during surgery; in the recovery room. Method of measurement: Measurement of systolic and diastolic blood pressure using invasive and noninvasive automatic blood pressure monitor.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: Before induction of anesthesia; after surgical incision; every fifteen minutes during surgery; in the recovery room. Method of measurement: Measurement of heart rate using an electrocardiographic cardiac monitor.</prim_outcome>
      <prim_outcome>Total intraoperative opioid consumption. Timepoint: From the beginning of anesthesia induction until the end of the surgical procedure. Method of measurement: Calculation of the total opioid dose based on values recorded by the anesthesia team in the anesthesia record.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Postoperative pain score measured by the Visual Analogue Scale. Timepoint: In the recovery room; two hours after surgery; four hours after surgery. Method of measurement: Measurement using a ten-centimeter Visual Analogue Scale for pain assessment.</sec_outcome>
      <sec_outcome>Postoperative nausea and vomiting. Timepoint: In the recovery room; two hours after surgery; four hours after surgery. Method of measurement: Clinical observation and documentation of nausea and vomiting events by the recovery room nurse.</sec_outcome>
      <sec_outcome>Sedation level assessed by the Ramsay Sedation Scale. Timepoint: In the recovery room; thirty minutes after admission to recovery. Method of measurement: Assessment using the Ramsay Sedation Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-10-27</approval_date>
        <contact_name>Research Ethics Committees of Imam Reza Hospital Educational, Research and Treatment Center- Mashhad</contact_name>
        <contact_address>Ibn Sina St., Imam Reza Hospital Square, Imam Reza Educational Research and Treatment Center mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
